diagnosis and pathology
The commonly used World Health Organization (WHO) classification distinguishes tumours according to their presumed cell of origin (astrocytes or oligodendrocytes), and grades them from grade I-IV [4] . Grade I tumours occur mainly in childhood, and grade II (or low-grade) glioma are slow-growing tumours but will almost invariably transform over time to a more malignant phenotype. Grade III tumours (also commonly referred to as anaplastic glioma) comprise anaplastic astrocytoma, mixed anaplastic oligoastrocytoma and anaplastic oligodendroglioma, while glioblastoma (GBM) represents WHO grade IV. Tissue diagnosis is mandatory, and usually obtained by stereotactic biopsy or after tumour resection. GBM carries the worst prognosis, while pure oligodendroglioma has a protracted natural history and better outcome, and excellent response to therapy. Prognosis of mixed anaplastic oligoastrocytoma and anaplastic astrocytoma is intermediate between GBM and pure anaplastic oligodendroglioma. Concordance between local diagnosis and central neuropathology review can be as low as 50%, thus careful review of the histology by an expert neuropathology team is recommended [5, 6] . Molecular markers are useful additional tools for diagnosis and treatment guidance (see below), and are of increasing importance in daily practice. Adequate tissue collection and preservation (e.g. sufficient material, fresh frozen tumour tissue) should be planned prospectively (see Table 1 ).
molecular markers
Genetic loss on chromosomes 1p/19q (co-deletion or loss of heterozygosity [LOH] 1p/19q) is a consequence of a chromosomal translocation and describes a distinct tumour entity characterised by a prolonged natural history irrespective of treatment, and increased sensitivity both to radiotherapy (RT) and to chemotherapy [7] . LOH 1p/19q should be evaluated to support a diagnosis of oligodendroglioma.
Mutations of the isocitrate dehydrogenase gene (IDH) were recognised in 2008 as an early event in glioma genesis [8] . Mutations in the IDH gene 1 or 2 are hallmarks of low-grade glioma; when observed in high-grade glioma, it suggests that the tumour has developed from a lower grade precursor lesion (secondary GBM) [9, 10] . Less than 10% of individuals with adult GBM carry an IDH mutation, while ∼60% of grade III tumours are IDH-mutated [8, 11] ; IDH-mutated tumours are associated with a more favourable prognosis [12, 13] . Indeed, the survival of IDH-mutated GBM is more favourable than for non-mutated grade III astrocytoma, thus underscoring the strong prognostic value of this finding [10, 12] . The more frequent IDH1 mutation accounts for ∼90% of all IDH mutations and can be demonstrated by immunohistochemistry, while IDH2 mutations and IDH1 mutations at other sites can only be identified by sequencing. In lower grade tumours or suspected transformed glioma, IDH sequencing should be carried out if staining by immunohistochemistry with the anti-IDH antibody (which recognises R132H mutation) is negative.
Epigenetic silencing of the methyl-guanine methyl transferase (MGMT) gene promoter by gene promoter methylation suggests a partial inability of the tumour to repair the chemotherapyinduced DNA damage [14] . In retrospective analyses, MGMT methylation has been correlated with a response to or benefit of alkylating agent chemotherapy [II, B] [15, 16] . MGMT determination by immunohistochemistry lacks standardisation, reproducibility and, most importantly, correlation with clinical outcome [III, C], while MGMT status determination by methylation-specific polymerase chain reaction (MSP) has been largely standardised and allows for reproducible results [17, 18] . A predictive value of a methylated MGMT status for response to or benefit from alkylating agent chemotherapy and thus improved outcome has been demonstrated repeatedly in GBM [19, 20] . However, in lower grade IDH-mutated tumours, MGMT methylation identifies a sub-population with a better prognosis irrespective of the applied treatment [18] .
The determination of these markers is now part of routine practice; however, whether MGMT methylation status determination is carried out for an individual patient depends on the diagnostic and therapeutic context ( [19, 20] . In current clinical trials, MGMT status is always required as a stratification factor. For a detailed discussion, the reader is referred to recent extensive reviews [18] .
These markers are neither mutually exclusive nor entirely independent. MGMT promoter methylation is highly associated with LOH 1p/19q and IDH mutations [11] . MGMT methylation is predictive for benefit from alkylating agent chemotherapy in GBM, while it confers a largely prognostic value in anaplastic grade III tumours. A recent report from the Neuro-Oncology Working Group (NOA) of the German Cancer Society confirmed a predictive value of MGMT methylation for benefit from chemotherapy in patients with a wild-type IDH, independent of tumour grade [21] .
staging and risk assessment
Although glioma are invasive tumours with a strong propensity of glioma cells to migrate, tumour dissemination remains limited to the central nervous system and distant metastases are virtually non-existent; thus, staging focuses on imaging of the brain, ideally by magnetic resonance imaging (MRI). The spine and cerebrospinal fluid (CSF) are not routinely assessed in the absence of clinical symptoms. Ideally, the extent of tumour resection and determination of residual disease should be assessed after surgery; however, this assessment must be carried out within 24-48 h in order to distinguish post-surgical contrast enhancement from residual tumour. Lower tumour grade, radical tumour resection, younger age (<50 years), good performance status and an intact neurological function are favourable prognostic factors. Determination of molecular markers (discussed above) will identify patients with a more favourable prognosis or better chance of response to alkylating agent chemotherapy.
disease management and treatment plan general management
Patients should be evaluated and the treatment plan determined by a specialised multidisciplinary team including neurosurgeons, medical and radiation oncologists, but also an expert neuropathologist and neuroradiologist. Special consideration should be given to performance status and neurological function. Corticosteroids (usually dexamethasone 8-16 mg/day, but lower doses may be just as effective) allow for rapid reduction of tumour-associated oedema and improve clinical symptoms. Patients' glucose levels need to be monitored. Steroids are not necessary in patients without increased intracranial pressure or in the absence of oedema-associated neurological deficits. There is no need for prolonged steroid therapy after tumour resection or for prophylaxis during radiotherapy in asymptomatic patients. Rapid tapering and discontinuation of corticosteroids is recommended in order to avoid toxicity associated with prolonged exposure to steroids, e.g. myopathy and weakness, lymphopenia and risk of infection, osteoporosis and Cushing syndrome.
Anti-epileptic therapy is indicated in patients presenting with seizures; however, prophylactic use of anticonvulsants outside the perioperative phase is not indicated [III, C] . After tumour resection, the indication for anti-seizure therapy should be revisited only if seizures occur [22, 23] . First generation anti-epileptic drugs ( phenytoin, carbamazepine, phenobarbital and their derivatives) are strong inducers of the hepatic metabolism, and may interfere with medications including many commonly used chemotherapy agents (but not with TMZ). Agents such as lamotrigine, levetiracetam, pregabalin or valproic acid are preferred.
Glioma patients are at increased risk of thromboembolic events due to a tumour-induced hyper-coagulable state, but also as a consequence of neurological deficits, immobilisation and steroid use [24] . Prophylactic anticoagulation is not recommended; however, a low threshold for excluding deep vein thrombosis and pulmonary emboli is indicated when suspicious symptoms occur. The presence of a brain tumour is not a contraindication for the use of standard anticoagulants in patients with proven thrombosis.
newly diagnosed patients
Surgery is commonly the initial therapeutic approach for tumour debulking and obtaining tissue for diagnosis. Tumour [26] . When microsurgical resection is not safely feasible (e.g. due to location of the tumour or impaired clinical condition of the patient), a biopsy should be carried out. In experienced hands, the diagnostic yield is >95% [18] . A sufficient amount of tissue should be obtained for molecular analyses, and open biopsies may yield more tissue to allow this compared with stereotactic biopsies. On freshly frozen specimens, molecular genetic analyses (LOH 1p/19q, MGMT promoter methylation) can be carried out even with small amounts of tissue, and this should be planned beforehand [27] . Implantation of chemotherapy-impregnated wafers (carmustine polymers) into the resection cavity before radiotherapy has been shown to marginally improve median survival compared with radiotherapy alone [II, B] [28] ; however, no prospective data are available when compared with current standard TMZ/ RT (see below) [29] . An increase in wound healing and infectious complications has been reported. Figure 1 ).
glioblastoma (WHO grade IV)
Concomitant and adjuvant TMZ chemotherapy in addition to radiotherapy (TMZ/RT → TMZ) significantly improved median, 2-and 5-year survival in a large randomised trial, and is the current standard of care for patients with GBM up to age 70 [34, 35] [32] , the 6-week regimen was inferior compared with hypo-fractionated RT in patients >70 years in a subsequent larger randomised trial [19, 32] , supporting the practice of administering RT as a short hypofractionated course in elderly patients. Primary chemotherapy versus radiotherapy has been compared in two randomised phase III trials reported in 2012 [19, 20] . Consistently, both trials have demonstrated a poor median overall survival (OS) of 7-9 months. MGMT promoter methylation was strongly predictive for a benefit from TMZ chemotherapy, suggesting that patients with a methylated MGMT are better treated with chemotherapy, while patients with an unmethylated MGMT should be managed with radiotherapy alone [II, A] [19, 20] . In the absence of information on the MGMT status, the appropriate treatment is hypofractionated radiotherapy [II, A] [33] . A randomised, controlled trial (clinicaltrials.gov: NCT#00482677) investigating hypofractionated RT ± concomitant and maintenance TMZ completed recruitment in 2013; first results are expected in late 2014.
Recent large phase III trials of novel treatment approaches failed to improve survival of patients with newly diagnosed GBM. Dose intensification of the adjuvant or maintenance TMZ therapy [36] , the addition of cilengitide [37] or the addition of bevacizumab [38, 39] [40, 41] , but benefit was mainly present in prognostically favourable molecular subgroups of patients (in particular co-deletion of 1p/19q) [II, B] . In a more recent randomised trial with follow-up data currently available up to 4.5 years, time to failure of both chemotherapy and radiation was similar whether patients were treated initially with chemotherapy (and received RT at first progression) or were treated with initial RT (and received chemotherapy at progression) [ Diffuse gliomas are low-grade tumours and comprise the histological subtypes of astrocytoma, oligoastrocytoma and oligodendroglioma. Although they have a protracted natural history of years or occasionally decades, and may not need immediate therapy, these tumours invariably recur and often transform into a higher histological grade.
The diagnosis is often made after an initial seizure is observed as a presenting symptom, or when imaging of the brain is carried out to investigate neurological deficits, changes in mood or personality. At that time, the tumour may already have grown to a substantial size without causing evident neurological dysfunction, due to its slow growth over many years.
Radical surgery both for diagnostic and therapeutic purposes is the backbone of low-grade glioma management. It is assumed that, by resection of all visible tumour tissue, the risk of subsequent malignant transformation is substantially reduced [III, B] .
In an exemplary randomised trial, investigators from the EORTC have demonstrated that an 'expectative' or cautious approach-delaying additional radiotherapy until symptoms prevail and the tumour has grown to >5-6 cm-will substantially delay or eliminate the need for irradiation in a significant number of patients [I, A] [43] . Adjuvant radiotherapy for a total dose of 50.4 Gy (28 × 1.8 Gy) is the accepted standard of care [I, A]. Two randomised trials investigated lower (45-50.4 Gy) versus higher dose (59.4-64.8 Gy) of irradiation; the lower dose was equivalent to the higher dose with less toxicity [44, 45] . Based on these trials, a number of negative prognostic factors were identified: tumour size >5-6 cm, tumours crossing the mid-line, absence of oligodendroglial histology, age >40 years and neurological deficits before surgery [46] . Three or more of these risk factors are considered an indication for adjuvant radiotherapy. A contemporary randomised trial compared adjuvant single-agent TMZ chemotherapy (without radiation) with standard radiotherapy. Preliminary results were presented at the American Society of Clinical Oncology meeting in 2013, and demonstrated that PFS analysis favours radiotherapy; however, follow-up is too early for firm conclusions and survival results are not yet mature [47] . Molecular characterisation of tumours may allow identification of subgroups of patients benefitting from one of the other treatment modalities, with 1p/19q codeleted tumours having a similar PFS after TMZ chemotherapy compared with radiotherapy. The Radiation Therapy Oncology Group (RTOG) has conducted a randomised trial in a similar population exploring the efficacy of adjuvant PCV chemotherapy after radiotherapy. At the time of first presentation, the follow-up data were immature; thus, definitive conclusions are not yet possible [48] .
recurrent disease
Some benefit of chemotherapy has been shown for patients with an adequate performance status who have not received prior [49, 50] . For patients progressing after prior chemotherapy, there is no established chemotherapy regimen available and patients are best treated within investigational clinical protocols. Chemotherapy with PCV or single-agent nitrosourea therapy may achieve similar tumour control rates compared with TMZ [51] [52] [53] . Randomised trials in recurrent glioblastoma have failed to demonstrate measurable anti-tumour efficacy of epidermal growth factor receptor (EGFR) inhibition by erlotinib or platelet-derived growth factor receptor inhibition by imatinib in an unselected patient population [II, C] [54, 55] . High response rates and a steroid-sparing effect have been observed with the administration of bevacizumab (± irinotecan); however, the effect is frequently short-lived and may be due exclusively to changes in vascular permeability; the effect on life expectancy remains unknown [III, C] [56, 57] . Randomised trials evaluating the pan-vascular endothelial growth factor receptor inhibitor cediranib or protein kinase C inhibitor enzastaurin failed to demonstrate improved outcome, and provide contemporary data on the limited but confirmed single-agent efficacy of lomustine (CCNU) [52, 53] . Applying alternating electric fields-tumour-treating fields (TTFs)-using a batterypowered device connected to electrodes placed on the patient's scalp-was compared with physicians' choice of chemotherapy in a randomised trial in recurrent disease [58] . TTF failed to prolong survival compared with second-line chemotherapy [I, A]. There may be an indication for a re-operation [IV, C], in particular in patients where the recurrent tumour exerts an acute mass effect. However, there are no prospective data available on the impact of repeat surgery on OS. Retrospective analyses on selected patients did not identify surgery for recurrent disease as a significant prognostic factor for prolonged survival [59, 60] . Repeat surgery and implantation of carmustine-impregnated polymers may lead to marginal prolongation of survival compared with placebo, as demonstrated in a randomised trial conducted in the early 1990s [II, B] [61] .
Re-irradiation is being considered increasingly for recurrent small tumours [IV, C], although there is considerable doubt about its benefit and the literature lacks prospective and comparative trials [62, 63] . The few limited size case series do not allow for any conclusion.
response evaluation
MRI is the preferred imaging method. Increased contrast enhancement and presumed tumour progression on imaging 4-12 weeks after the end of radiotherapy may be due to a reactive process following radiotherapy ( pseudo-progression) [64, 65] . Early presumed progression after the end of radiotherapy should raise the possibility of pseudo-progression, and chemotherapy should be continued as planned with repeat imaging after 6-8 weeks. An incidence of >60% pseudo-progression has been reported among patients with early radiological progression after radiochemotherapy [66] .
Response to chemotherapy is currently evaluated according to the 2D Response Assessment in Neuro-Oncology (RANO) criteria, in which in addition to contrast enhancement, tumour extension on T 2 -and fluid-attenuated inversion recovery (FLAIR)-weighted MRI are evaluated [67] . Furthermore, an assessment of neurological function and corticosteroid use is included. The recent introduction of anti-angiogenic and vascular modifying agents led to a reassessment of response criteria, in which, in addition to contrast enhancement, tumour extension on T 2 -and FLAIR-weighted MRI are to be evaluated [67] . In cases of doubtful differential diagnosis between tumour recurrence and treatment-induced unspecific changes (especially after multimodal therapy), magnetic resonance spectroscopy and positron-emission tomography investigation using an amino acid tracer (e.g. methionine, fluoro-ethyl-tyrosine) may be helpful [III, B] [68] . However, often both residual tumour and necrotic and inflammatory changes are present in the same lesion.
personalised medicine
Recent investigation of molecular markers, gene expression, whole genome sequencing and epigenetics has enabled identification of patient subgroups according to pathway activation, specific aberrations or pathognomonic molecular characteristics [69] . The clinical utility of IDH mutations, LOH 1p/19q and MGMT promoter methylation in prognostication and their predictive value and role in clinical decision-making have been discussed in the relevant subheadings above. ATRX mutations have been identified to be specific for astrocytic lineage. Other markers like EGFR overexpression and EGFR variant III (EGFRviii) mutation are characteristic for GBM that carry an inferior prognosis (reviewed in [70] ). Targeting the EGFR with specific inhibitors and vaccination against EGFRviii are currently under clinical investigation [71] . Rare activating BRAF mutations can be identified in 3%-5% of GBM; whether the BRAF inhibitors are effective (alone or in combination) in this subgroup of tumours is subject of ongoing clinical research protocols. All planned investigational protocols are being designed for specific subgroups, selecting and enriching for specific molecular aberrations when targeting activated pathways.
follow-up and long-term implications
Follow-up consists of a clinical evaluation with particular attention to neurological function, seizures and corticosteroid use. Patients should be tapered off steroid use as early as possible. Venous thrombotic events occur frequently in patients with residual or recurrent tumours. Laboratory tests are not indicated unless the patient is receiving chemotherapy (blood counts), corticosteroids (glucose) or anti-epileptic drugs (blood count, liver function tests). MRI every 3-4 months is standard practice outside clinical trials, unless more frequent monitoring is clinically indicated. note A summary of recommendations is provided in Table 3 . Levels of evidence and grades of recommendation have been applied using the system shown in 
